StabyDNA enables clone selection, plasmid stability, and production.

Eurogentec Biologics will promote Delphi Genetics’ StabyDNA platform for GMP manufacturing on an exclusive basis. Delphi Genetics reports that this antibiotic resistance gene-free technology allows for clone selection, plasmid stability, and manufacturing of plasmids and proteins without the use of antibiotics.


U.S and European regulatory agencies have reportedly recommended steering away from using antibiotic-resistance genes in the manufacturing process of biotherapeutics, as these resistance genes have no therapeutic value in the final product. Many plasmid DNA biologics currently going through clinical development contain antibiotic-resistance genes, according to Delphi and Eurogentec.


“The StabyDNA technology offers benefits in terms of GMP manufacturing and FDA and EMEA concerns about the use of antibiotics, offering real value to future sponsors of plasmid DNA clinical trials,” remarks Florence Xhonneux, biologics business development manager at Eurogentec.

Previous articleDISCOVERING DRUGS AND BIOFUELS IN TROPICAL SEAS
Next articleBioSeek Choses Two Anti-Inflammatory Peptides from Alliance with Amylin